A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Lowest Effective Dose of Combinations of Drospirenone and 17 Beta-Estradiol for the Relief of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Lowest Effective Dose of Combinations of Drospirenone and 17 Beta-Estradiol for the Relief of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Estradiol/drospirenone (Primary) ; Estradiol
  • Indications Hot flashes
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 17 May 2011 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
    • 25 Jan 2011 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Patient numbers amended from 910 to 735 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top